Related Experiment Video

Updated: Apr 20, 2026

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells
13:38

Synthesis and Characterization of an Aspirin-fumarate Prodrug that Inhibits NFκB Activity and Breast Cancer Stem Cells

Published on: January 18, 2017

12.8K

The FGF/FGFR axis as a therapeutic target in breast cancer

Nicholas Brady1, Polly Chuntova1, Lindsey K Bade2

  • 1Microbiology, Immunology and Cancer Biology Graduate Program, University of Minnesota, 420 Delaware St. SE, MMC 609, Minneapolis, MN 55455.

Expert Review of Endocrinology & Metabolism
|November 18, 2014
PubMed

Insights

Fibroblast growth factor receptor (FGFR) signaling is crucial for mammary gland development and its dysregulation drives breast cancer. Small molecule FGFR inhibitors are being investigated in clinical trials for therapeutic potential.

Area of Science:

  • Oncology
  • Cell Biology
  • Developmental Biology

Background:

  • Fibroblast growth factor receptor (FGFR) signaling is essential for mammary gland development.
  • Deregulated FGFR signaling is implicated in breast cancer pathogenesis.
  • FGFRs represent a potential therapeutic target in oncology.

Purpose of the Study:

  • To review recent discoveries in FGF/FGFR signaling in breast cancer.
  • To highlight the role of FGF/FGFR signaling as an oncogenic driver.
  • To discuss the potential of FGFR inhibitors as a therapeutic strategy.

Main Methods:

  • Review of recent experimental outcomes from animal models and human cell lines.
  • Analysis of mechanisms driving deregulated FGFR signaling in breast cancer.
  • Examination of data from early-phase clinical trials of FGFR inhibitors.

Main Results:

  • Deregulated FGFR signaling in breast cancer involves gene amplification, aberrant ligand expression, mutations, and translocations.
  • Multiple clinical trials are evaluating small molecule FGFR inhibitors.
  • FGFR signaling pathways are critical oncogenic drivers.

Conclusions:

  • FGFR signaling plays a vital role in breast cancer development and progression.
  • Targeting FGFRs with inhibitors shows therapeutic promise.
  • Further investigation into FGF/FGFR signaling mechanisms is warranted.
Keywords:
Breast cancerfibroblast growth factorfibroblast growth factor receptormammary glandreceptor tyrosine kinasetargeted therapies

More Related Videos

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library07:32

Screening and Identification of Small Peptides Targeting Fibroblast Growth Factor Receptor2 using a Phage Display Peptide Library

Published on: September 30, 2019

8.4K
Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures07:48

Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures

Published on: December 26, 2016

12.0K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.2K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.5K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
5.1K
TGF - β Signaling Pathway01:16

TGF - β Signaling Pathway

The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
11.1K
Transducer Mechanism: G Protein–Coupled Receptors01:30

Transducer Mechanism: G Protein–Coupled Receptors

G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
9.0K